Veraxa Biotech has entered a joint discovery partnership with OmniAb tp develop a bispecific antibody drug conjugate (bsADC) ...

Alphamab has developed JSKN021, a dual payload bispecific ADC targeting EGFR/HER3, utilizing glycan-specific conjugation technology. The novel DNA topoisomerase I inhibitor T01 and the microtubule ...

IBI3014 is a bispecific ADC targeting TROP2 and PD-L1. Its dual mechanism integrates TROP2-directed tumor killing with PD-L1 immune checkpoint blockade, enhancing immunogenic cell death and T cell ...

a TROP2xPD-L1 bi-specific ADC integrating ADC killing with checkpoint blockade within one molecule, exhibits promising efficacy and safety in preclinical models IBI3014 is a bispecific ADC targeting ...

These data support the clinical development of IBI3010 to evaluate its potential as an ADC therapeutic for FRα-expressing solid tumors. IBI3014 is a bispecific ADC targeting TROP2 and PD-L1.